^
    Back
    Association details:
    Biomarker:UBE3A deletion
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Bioengineered
    Title:

    UBE3A deletion enhances the efficiency of immunotherapy in non-small-cell lung cancer

    Excerpt:
    Our study aimed to identify markers that can precisely forecast the efficacy of immunotherapy in patients….By analyzing an ICI dataset from MSKCC, we found that progression-free survival (PFS) was improved after UBE3A deletion (UBE3A-del).
    DOI:
    10.1080/21655979.2022.2069328